Top Markets
Coin of the day
Kazia Therapeutics Limited Kazia Therapeutics Limited

Kazia Therapeutics Limited

KZA
Rangering i aksjer #35840
Kazia Therapeutics Limited is a biotechnology firm specializing in oncology,... Kazia Therapeutics Limited is a biotechnology firm specializing in oncology, committed to developing innovative therapies for cancer. Its flagship product candidate, Paxalisib, is a brain-penetrant small molecule that inhibits the PI3K/Akt/mTor pathway and is currently being investigated as a potential treatment for glioblastoma. Additionally, the company is progressing EVT801, an investigational new drug aimed at combating various types of cancer. Established in 1994 and headquartered in Sydney, Australia, the entity was formerly known as Novogen Limited before adopting the name Kazia Therapeutics Limited in November 2017.
Aksjekurs
$0.05207079
Sist synkronisert: 2023-11-15
Markedsverdi
$3.38M
Endring (1 dag)
0.13%
Endring (1 år)
0.00%
Land
AU
Handel Kazia Therapeutics Limited (KZA)

Kategori

EPS for Kazia Therapeutics Limited (KZA)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Kazia Therapeutics Limited er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Kazia Therapeutics Limited fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter